Jean-Luc TREILLOU

At DESKi, we focus on creating a smarter path to heart exams for all, actively taking on the world’s #1 killer, Heart Disease. By leveraging the skills of our audacious and committed team, we created HeartFocus in 2023, a ground-breaking AI-powered software, designed to let any healthcare professional perform heart exams with precision, anywhere. Based in Bordeaux, France, our team is international, committed and believe No heart can wait ™

Lucine is part of Butterfly Therapeutics since december 2023. Lucine is an expert in women’s pelvic pain relief, and we’re on a mission to change women’s lives. We offer an evidence-based approach with scientifically proven solutions that reduce & relieve pain related to endometriosis, periods, menopause, post-partum discomfort, and more. Endocare is our clinically-tested, patented medical device that directly targets pain mechanisms with a unique combination of visual and sound frequencies Lets work together, changing womens lives !

At DESKi, we focus on creating a smarter path to heart exams for all, actively taking on the world’s #1 killer, Heart Disease. By leveraging the skills of our audacious and committed team, we created HeartFocus in 2023, a ground-breaking AI-powered software, designed to let any healthcare professional perform heart exams with precision, anywhere. Based in Bordeaux, France, our team is international, committed and believe No heart can wait ™

Api, ce sont des supérettes nouvelles, connectées et toujours ouvertes, implantées dans les villages désertés par les services, qui remplissent leur fonction originelle et essentielle de proximité et de lien social, que la campagne mérite de retrouver.

Lucine is part of Butterfly Therapeutics since december 2023. Lucine is an expert in women’s pelvic pain relief, and we’re on a mission to change women’s lives. We offer an evidence-based approach with scientifically proven solutions that reduce & relieve pain related to endometriosis, periods, menopause, post-partum discomfort, and more. Endocare is our clinically-tested, patented medical device that directly targets pain mechanisms with a unique combination of visual and sound frequencies Lets work together, changing womens lives !

Expertise in cybersecurity testing takes years to build but can be lost in seconds. When tools are disconnected, teams work in silos, and critical knowledge isn’t shared, security weakens. We believe in a holistic approach, where tools, teams, and expertise are interconnected in a single environment to ensure efficiency, consistency, and long-term knowledge retention. At eShard, we help industrial leaders and government agencies take control of 𝗰𝗵𝗶𝗽 𝘀𝗲𝗰𝘂𝗿𝗶𝘁𝘆 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 and 𝗯𝗶𝗻𝗮𝗿𝘆 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀. Our platform provides a dedicated testing environment where teams can analyze vulnerabilities, assess security risks, and refine their expertise without the risk of losing critical knowledge when key people move on. Alongside our software platform, we provide hardware equipment, training services, and security assessments to ensure teams have the right resources and skills to tackle real-world security challenges. We are fully independent and self-funded company, committed to equipping security teams all around the world with the right tools and expertise to master risks, strengthen systems, and make informed decisions.

TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 150 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M in 2021 to advance its pipeline of stem cell-based therapies in the field of regenerative medicine with the lead program in Parkinsons Disease. In 2022, the company opened a technological hub in Boston, USA to drive the adoption of C-Stem and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.